NCT03790085 is a EARLY_PHASE1 clinical trial of Risperidone in Schizophrenia, sponsored by Tianjin Medical University General Hospital.

Who is sponsoring NCT03790085?

NCT03790085 is sponsored by Tianjin Medical University General Hospital.

What drugs are being tested in NCT03790085?

Interventions in NCT03790085: Risperidone, Olanzapine, Aripiprazole.

What condition does NCT03790085 study?

NCT03790085 studies Schizophrenia, Major Depressive Disorder, Anxiety Disorders.

Is NCT03790085 still recruiting?

NCT03790085 is currently status unknown. Last updated 31 December 2018.

Last reviewed 2018-12-31 · How we verify

NCT03790085

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals

Status unknown EARLY_PHASE1 Last updated 31 December 2018

What this trial tests

EARLY_PHASE1 trial testing Risperidone in Schizophrenia in 2,700 participants. Status unknown.

Timeline

1 September 2018

Primary endpoint
30 June 2020

31 December 2020

Quick facts

Lead sponsor	Tianjin Medical University General Hospital
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	2,700
Start date	1 September 2018
Primary completion	30 June 2020
Estimated completion	31 December 2020
Sites	1 location across China

Drugs / interventions tested

Risperidone (risperidone) — full drug profile →
Olanzapine (olanzapine) — full drug profile →
Aripiprazole (aripiprazole) — full drug profile →

Conditions studied

Schizophrenia — all drugs for Schizophrenia →
Major Depressive Disorder — all drugs for Major Depressive Disorder →
Anxiety Disorders — all drugs for Anxiety Disorders →

Sponsor

Tianjin Medical University General Hospital

Who can join

Adults 18 to 45, any sex, with Schizophrenia or Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to screen and validate multi-scale bio-markers for early diagnosis and medication monitoring for early schizophrenia, including the genetic, neurobiochemistry, neuroimaging and eletrophysiological measures. Based on the validated bio-markers, the present study further tries to build several prediction models for early differential diagnosis of schizophrenia from healthy controls and other mental diseases (such as the major depression and anxiety disorders), biological sub-typing and diagnosis of the schizophrenia sub-types, and early prediction of the medication effects.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Association of anhedonia with brain-derived neurotrophic factor and interleukin-10 in major depressive disorder.
Fu L, Ren J, Lei X, Wang Y, et al · · 2024 · cited 6× · PMID 38701878 · DOI 10.1016/j.pnpbp.2024.111023
Characterizing Unipolar and Bipolar Depression by Alterations in Inflammatory Mediators and the Prefrontal-Limbic Structural Network.
Lei X, Ren J, Teng X, Guo C, et al · · 2023 · cited 1× · PMID 40224600 · DOI 10.1155/2023/5522658
Effects of theta burst stimulation on cognitive function and characteristics of blood oxygen alterations based on near-infrared spectroscopy in chronic schizophrenia.
Gao C, Li G, Zhang X, Lu T, et al · · 2025 · PMID 40797243 · DOI 10.1186/s12888-025-07240-1
Plasma Apo-E mediated corticospinal tract abnormalities and suicidality in patients with major depressive disorder.
Lei X, Fang X, Ren J, Teng X, et al · · 2024 · PMID 38265467 · DOI 10.1007/s00406-023-01749-w

Verify or expand the search:

Other trials of Risperidone

Trials testing the same drug.

NCT07503002 — Shortened LSD Intervention for Major Depressive Disorder · Phase 1 · not yet recruiting
NCT07483294 — Cerebellum-based Imaging Neural Markers for Antipsychotic Response · recruiting
NCT07060872 — the Effect of Formulation on Anxiety in Autist Childre A Randomized Controlled Trial Assesses Spirulina Syrup Plus Rispe · NA · not yet recruiting
NCT06236451 — Atypical Antipsychotic-induced Mitochondrial Dysfunction in Patients With Schizophrenia · Phase 4 · completed
NCT06368726 — Result of tDCS in ASD Children With Comorbidities Like PANDAS, Rare Genetic Diseases or Autoimmune Disorders · Phase 1 · enrolling by invitation

Other recruiting trials for Schizophrenia

Currently open trials in the same condition.

NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting

Other Tianjin Medical University General Hospital trials

Trials by the same sponsor.

NCT06228781 — Autologous Hematopoietic Stem Cell Transplantation for Refractory Multiple Sclerosis · NA · not yet recruiting
NCT07498595 — TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC · EARLY_PHASE1 · not yet recruiting
NCT07498439 — TILs Therapy for Multiple Primary Early-Stage NSCLC · EARLY_PHASE1 · not yet recruiting
NCT07018375 — The Effect of Oliceridine Patient-Controlled Intravenous Analgesia on Postoperative Chronic Pain After Video-Assisted Th · Phase 4 · not yet recruiting
NCT07420296 — Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03790085 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University General Hospital
Last refreshed: 31 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03790085.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing